Q1 2022 EPS Estimates for FibroGen, Inc. (NASDAQ:FGEN) Reduced by Analyst

FibroGen, Inc. (NASDAQ:FGENGet Rating) – Analysts at William Blair reduced their Q1 2022 earnings per share (EPS) estimates for shares of FibroGen in a report released on Monday, April 18th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will post earnings per share of ($0.50) for the quarter, down from their previous forecast of ($0.39). William Blair also issued estimates for FibroGen’s Q2 2022 earnings at ($0.49) EPS, Q3 2022 earnings at ($0.48) EPS, Q4 2022 earnings at ($0.47) EPS, FY2022 earnings at ($1.93) EPS, FY2023 earnings at ($1.80) EPS and FY2024 earnings at ($1.73) EPS.

Several other analysts have also recently commented on the stock. Zacks Investment Research raised shares of FibroGen from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 3rd. StockNews.com assumed coverage on shares of FibroGen in a research note on Thursday, March 31st. They set a “hold” rating for the company. Finally, The Goldman Sachs Group lowered their price objective on shares of FibroGen from $10.00 to $9.00 and set a “sell” rating for the company in a research note on Tuesday, March 1st. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $20.43.

FGEN stock opened at $10.62 on Wednesday. The stock has a market capitalization of $987.68 million, a P/E ratio of -3.38 and a beta of 0.79. FibroGen has a one year low of $9.88 and a one year high of $30.12. The company has a 50 day moving average price of $13.22 and a two-hundred day moving average price of $13.14.

FibroGen (NASDAQ:FGENGet Rating) last released its earnings results on Monday, February 28th. The biopharmaceutical company reported ($1.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.77). The firm had revenue of $16.54 million during the quarter, compared to analysts’ expectations of $47.65 million. FibroGen had a negative return on equity of 93.23% and a negative net margin of 123.25%. The firm’s revenue was down 74.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.64) earnings per share.

Institutional investors have recently made changes to their positions in the stock. National Bank of Canada FI purchased a new stake in FibroGen during the 4th quarter worth $33,000. Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in FibroGen during the 1st quarter worth $59,000. Point72 Hong Kong Ltd purchased a new stake in FibroGen during the 3rd quarter worth $65,000. Royal Bank of Canada boosted its position in FibroGen by 20.6% during the 3rd quarter. Royal Bank of Canada now owns 7,451 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 1,271 shares during the period. Finally, Advisor Group Holdings Inc. boosted its position in FibroGen by 90.6% during the 4th quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 4,236 shares during the period. 75.75% of the stock is owned by hedge funds and other institutional investors.

About FibroGen (Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.